1. Home
  2. EXG vs NAMS Comparison

EXG vs NAMS Comparison

Compare EXG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest

EXG

Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest

N/A

Current Price

$8.67

Market Cap

2.9B

Sector

Finance

ML Signal

N/A

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

N/A

Current Price

$18.51

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EXG
NAMS
Founded
N/A
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.8B
IPO Year
2006
2022

Fundamental Metrics

Financial Performance
Metric
EXG
NAMS
Price
$8.67
$18.51
Analyst Decision
Strong Buy
Analyst Count
0
16
Target Price
N/A
★ $50.86
AVG Volume (30 Days)
538.1K
★ 1.8M
Earning Date
01-01-0001
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.81
EPS
★ N/A
N/A
Revenue
N/A
★ $22,503,000.00
Revenue This Year
N/A
$83.53
Revenue Next Year
N/A
$23.31
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$8.25
$17.90
52 Week High
$10.16
$42.21

Technical Indicators

Market Signals
Indicator
EXG
NAMS
Relative Strength Index (RSI) 27.45 38.25
Support Level $8.25 N/A
Resistance Level $9.63 $22.28
Average True Range (ATR) 0.19 1.34
MACD -0.07 0.02
Stochastic Oscillator 1.89 12.50

Price Performance

Historical Comparison
EXG
NAMS

About EXG Eaton Vance Tax-Managed Global Diversified Equity Income Fund of Beneficial Interest

Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: